SCHEMBL376424

SCHEMBL376424

COC1(Cc2ccccc2Cl)CCC(N2CCN(/C(=N/C#N)SC)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 8/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.40
CCR5 P51681 3/20 0.38
MAPK1 P28482 2/20 0.35
CCR1 P32246 1/20 0.33
PGR P06401 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376425 1.00 MAPT (0.43) MAPTHTTALDH1A1CYP2D6CYP2C9
SCHEMBL377038 0.90 ALDH1A1 (0.47) MAPTHTTALDH1A1CYP2D6CYP2C9
SCHEMBL377039 0.90 ALDH1A1 (0.47) MAPTHTTALDH1A1CYP2D6CYP2C9
SCHEMBL376371 0.89 MAPT (0.43) MAPTHTTALDH1A1CYP2D6CYP2C9
SCHEMBL376628 0.89 MAPT (0.43) MAPTHTTALDH1A1CYP2D6CYP2C9
SCHEMBL381715 0.87 MAPT (0.49) MAPTHTTALDH1A1CYP2D6CYP2C9
SCHEMBL381716 0.87 MAPT (0.49) MAPTHTTALDH1A1CYP2D6CYP2C9
SCHEMBL376500 0.76 MAPT (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL376739 0.75 KMT2A (0.39) ALDH1A1CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL13503546 0.65 SLC6A2 (0.36) HTTALDH1A1CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD MAPT 4433/4885HTT 2129/4885ALDH1A1 2354/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD MAPT 4433/4885HTT 2129/4885ALDH1A1 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.